MOLCURE Inc. today announced that it has signed a new agreement with Teijin Pharma Limited to continue joint research in antibody drug discovery leveraging MOLCURE’s AI-driven platform. The agreement follows the strong results of their previous collaboration.
“We are delighted to have signed a new agreement with Teijin Pharma, building on the success of our earlier collaboration,” said Dr. Satoshi Tamaki, CEO and CSO of MOLCURE. “Teijin Pharma’s continued adoption of our AI-based lead optimization technology and drug discovery approach reflects the strength and reliability of our platform. We are proud to support the advancement of Teijin Pharma’s drug discovery programs and help accelerate the development of innovative therapeutics. We look forward to continuing this partnership so that new treatments can improve outcomes and quality of life for patients around the world.”
About MOLCURE
MOLCURE Inc. is a leader in AI-driven drug discovery for antibodies and peptides. Our platform combines cutting-edge large language models (LLMs), physics-based simulations, and high-quality experimental data from our in-house labs. This approach enables the discovery of innovative biologics that are safer and more effective, making it possible to tackle undrugged targets that other technologies cannot reach. We work with forward-thinking partners, including leading pharmaceutical companies, to accelerate R&D and help bring life-changing new treatments for patients around the world. Founded in 2013, MOLCURE is based in Japan, with headquarters in Kawasaki and a research facility in Tsuruoka. Learn more at https://molcure.com.
About the Teijin Group
Teijin (TSE: 3401) is a technology-driven global group with two core businesses: high-performance materials and healthcare solutions. Established in 1918 as Japan’s first rayon manufacturer, Teijin today comprises some 150 companies employing 20,000 people. Teijin is committed to its Purpose, “Pioneering solutions together for a healthy planet.” Teijin works together with employees and external partners to achieve its Long-Term Vision, “To be a company that supports the society of the future.” Teijin posted consolidated sales of JPY 1,005.5 billion and total assets of JPY 1,061.3 billion in the fiscal year ending March 31, 2025.
For media and business inquiries:
Tsunehiko Kohashi
MOLCURE Inc.
contact＠molcure.io
044-400-1894
